Cargando…
P2RX7B is a new theranostic marker for lung adenocarcinoma patients
Rationale: The characterization of new theranostic biomarkers is crucial to improving the clinical outcome of patients with advanced lung cancer. Here, we aimed at characterizing the P2RX7 receptor, a positive modulator of the anti-tumor immune response, in patients with lung adenocarcinoma. Methods...
Autores principales: | Benzaquen, Jonathan, Dit Hreich, Serena Janho, Heeke, Simon, Juhel, Thierry, Lalvee, Salomé, Bauwens, Serge, Saccani, Simona, Lenormand, Philippe, Hofman, Véronique, Butori, Mathilde, Leroy, Sylvie, Berthet, Jean-Philippe, Marquette, Charles-Hugo, Hofman, Paul, Vouret-Craviari, Valérie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532666/ https://www.ncbi.nlm.nih.gov/pubmed/33042257 http://dx.doi.org/10.7150/thno.48229 |
Ejemplares similares
-
Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
por: Janho dit Hreich, Serena, et al.
Publicado: (2023) -
Alternative splicing of P2RX7 pre-messenger RNA in health and diseases: Myth or reality?
por: Benzaquen, Jonathan, et al.
Publicado: (2019) -
The Role of IL-18 in P2RX7-Mediated Antitumor Immunity
por: Janho dit Hreich, Serena, et al.
Publicado: (2023) -
The Purinergic Landscape of Non-Small Cell Lung Cancer
por: Janho dit Hreich, Serena, et al.
Publicado: (2022) -
MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma
por: Bozec, Alexandre, et al.
Publicado: (2017)